Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol
Public ClinicalTrials.gov record NCT07881601. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effects of Reduced and Oxidized CoQ10 on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, double-blind, placebo-controlled clinical trial will evaluate the effects of Ubiquinol and Ubiquinone on vascular endothelial function in generally healthy adults with borderline high LDL-cholesterol. Participants will receive Ubiquinol 200 mg/day, Ubiquinone 200 mg/day, or placebo for 8 weeks. The primary outcome is change in flow-mediated dilation (FMD), a measure of vascular endothelial function, assessed at baseline, Week 4, and Week 8. The study will also evaluate changes in plasma CoQ10 levels, nitric oxide, LDL oxidation susceptibility, oxidative stress markers, and treatment-emergent adverse events.
Study identification
- NCT ID
- NCT07881601
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- Ubiquinol Dietary Supplement
- Ubiquinone Dietary Supplement
- Placebo Other
Dietary Supplement · Other
Eligibility (public fields only)
- Age range
- 35 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 17, 2026 (Estimated)
- Primary completion
- Dec 19, 2026 (Estimated)
- Completion
- Jan 22, 2027 (Estimated)
- Last update posted
- Oct 19, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| San Francisco Research Institute | San Francisco | California | 94132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07881601, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07881601 live on ClinicalTrials.gov.